LungLife AI, Inc
LLAI:LN
Latest Coverage
Overview
Company Profile
LungLife AI is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence.
Classification
Financials
News & Media
Latest Coverage
Corporate
Board of Directors
Roy Davis
Non-Executive Chairman
Roy has extensive experience spanning medical devices, diagnostics, and the digital healthcare space. He is currently Chairman of Medica Group PLC, the UK’s leading teleradiology company, Edinburgh Molecular Imaging Limited, a cancer theragnostic imaging company, Foster & Freeman Limited, a leading forensic imaging manufacturer and RAIR Health Limited, an applied AI and health data company. Prior to these roles, Roy served as the chief executive officer of Optos plc, a leading ophthalmology medical device business, from 2008 until June 2016 when he stepped down following the company’s acquisition by Nikon Corporation. Before joining Optos, he served from 2007 as chief executive officer of Gyrus Group plc, a leading medical device company, prior to its acquisition by the Olympus Corporation of Japan in 2008, having previously served as COO of Gyrus from 2003 and a Non-Executive Director since its IPO in 1997. Prior to this, Roy was the CEO of NTERA, a nanotechnology company, and before that spent almost ten years with Arthur D Little, the global management consulting company, where he was Vice President and Global Head of its operations management business.
Paul Pagano, PhD
Executive Director
Paul Pagano is the CEO of the Company and has over 15 years of experience in the sciences covering chemistry, engineering, and cancer biology. He was trained at UCLA in translational lung cancer research and has multiple publications spanning early disease pathogenesis and resistance to targeted lung therapy. Paul has spent the last five years at the Company leading research and development teams in developing clinical diagnostics for lung cancer using liquid biopsy. Paul has held positions at Cynvenio Biosystems Inc (formerly known as CytomX Therapeutics, Inc.) where he developed and patented a microfluidic platform for circulating tumor cell enrichment and analysis, and at Amgen Inc. in quality analytical laboratories. Prior to Amgen Inc., he worked in Human Resources at State Farm Insurance, one of the leading property and casualty insurance providers in the US, where he facilitated the California zone restructuring and consolidation efforts that resulted in significant operational cost savings. Paul received a B.S. from UC Santa Barbara in microbiology and immunology, and earned a PhD in pharmacology from the David Geffen School of Medicine at UCLA.
David Anderson
Executive Director
David is a chartered accountant and member of the Institute of Chartered Accountants of England and Wales with over 25 years’ experience of senior finance roles. He qualified with Stoy Hayward (now BDO LLP) and from 1998 to 2009 was an audit partner in their London office before becoming an audit partner with Crowe Clark Whitehill (now Crowe UK LLP) from 2010 to 2012. Since then he has held senior finance roles with Strategic Minerals Plc, Hakkasan and C|T Group. He is currently the CFO of Verici Dx Plc. David received a BSc(Econ) from the London School of Economics.
Andrew Boteler
Non-Executive Director
Andrew is a UK qualified chartered accountant and currently CFO of Riverford Organic Farmers Limited and Non-Executive Director of Octopus VCT plc. From 2009 to 2019, Andrew was CFO of Gooch & Housego PLC and in addition, was responsible for legal, investor relations and IT. He has had over 25 years working in the manufacturing sector, spending 19 of those years with high technology manufacturing companies. Andrew is experienced in M&A and fund raising, including management buy-out, trade sales and bank funding.
James McCullough
Non-Executive Director
James McCullough is the CEO of Renalytix AI (AIM:RENX, NASDAQ:RNLX) and has experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. Prior to his role at Renalytix AI, James served as CEO of Exosome Diagnostics, a venture capital backed personalized medicine company developing noninvasive liquid biopsy diagnostics in cancer, which was acquired by Bio-Techne in 2018. He is a managing partner at Renwick Capital, LLC and also serves on the board of directors of Verici Dx Plc, Kantaro Biosciences and the GO2 Foundation for Lung Cancer. James has served as a board Director for LungLife AI since 2019.
Sara Barrington
Non-Executive Director
Sara is CEO of Verici Dx (AIM:VRCI) and CCO of Kantaro Biosciences, LLC. Sara previously served as CEO of the Company from January 2019 to May 2020. She has held numerous senior roles including EVP of Business Operations with Bruin Biometrics, CFO of Exosome Diagnostics, and CFO at AusAm Biotechnologies. Prior to working in the US, she worked for British Telecom in London in business development and strategy. Sara is qualified as a Chartered Accountant with the Institute of Chartered Accountants in England and Wales. She has also qualified with Chartered Institute of Marketing.